| D007150 |
Immunohistochemistry |
Histochemical localization of immunoreactive substances using labeled antibodies as reagents. |
Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling |
|
| D010523 |
Peripheral Nervous System Diseases |
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. |
Peripheral Nerve Diseases,Peripheral Neuropathies,PNS (Peripheral Nervous System) Diseases,PNS Diseases,Peripheral Nervous System Disease,Peripheral Nervous System Disorders,Nerve Disease, Peripheral,Nerve Diseases, Peripheral,Neuropathy, Peripheral,PNS Disease,Peripheral Nerve Disease,Peripheral Neuropathy |
|
| D011379 |
Prognosis |
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. |
Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D012509 |
Sarcoma |
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. |
Sarcoma, Epithelioid,Sarcoma, Soft Tissue,Sarcoma, Spindle Cell,Epithelioid Sarcoma,Epithelioid Sarcomas,Sarcomas,Sarcomas, Epithelioid,Sarcomas, Soft Tissue,Sarcomas, Spindle Cell,Soft Tissue Sarcoma,Soft Tissue Sarcomas,Spindle Cell Sarcoma,Spindle Cell Sarcomas |
|
| D013584 |
Sarcoma, Synovial |
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363) |
Synovioma,Sarcomas, Synovial,Synovial Sarcoma,Synovial Sarcomas,Synoviomas |
|
| D016023 |
Integrins |
A family of transmembrane glycoproteins (MEMBRANE GLYCOPROTEINS) consisting of noncovalent heterodimers. They interact with a wide variety of ligands including EXTRACELLULAR MATRIX PROTEINS; COMPLEMENT, and other cells, while their intracellular domains interact with the CYTOSKELETON. The integrins consist of at least three identified families: the cytoadhesin receptors (RECEPTORS, CYTOADHESIN), the leukocyte adhesion receptors (RECEPTORS, LEUKOCYTE ADHESION), and the VERY LATE ANTIGEN RECEPTORS. Each family contains a common beta-subunit (INTEGRIN BETA CHAINS) combined with one or more distinct alpha-subunits (INTEGRIN ALPHA CHAINS). These receptors participate in cell-matrix and cell-cell adhesion in many physiologically important processes, including embryological development; HEMOSTASIS; THROMBOSIS; WOUND HEALING; immune and nonimmune defense mechanisms; and oncogenic transformation. |
Integrin |
|
| D018219 |
Histiocytoma, Benign Fibrous |
A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747) |
Dermatofibroma,Hemangioma, Sclerosing,Histiocytoma, Cutaneous,Histiocytoma, Fibrous,Angioma, Sclerosing,Benign Fibrous Histiocytoma,Angiomas, Sclerosing,Benign Fibrous Histiocytomas,Cutaneous Histiocytoma,Cutaneous Histiocytomas,Dermatofibromas,Fibrous Histiocytoma,Fibrous Histiocytoma, Benign,Fibrous Histiocytomas,Fibrous Histiocytomas, Benign,Hemangiomas, Sclerosing,Histiocytomas, Benign Fibrous,Histiocytomas, Cutaneous,Histiocytomas, Fibrous,Sclerosing Angioma,Sclerosing Angiomas,Sclerosing Hemangioma,Sclerosing Hemangiomas |
|
| D018317 |
Nerve Sheath Neoplasms |
Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category. |
Nerve Sheath Neoplasm,Nerve Sheath Tumor,Perineurioma,Peripheral Nerve Sheath Tumor,Peripheral Nerve Sheath Tumors,Neoplasms, Nerve Sheath,Nerve Sheath Tumors,Nerve Sheath Tumors, Peripheral,Tumors of the Nerve Sheath,Neoplasm, Nerve Sheath,Perineuriomas,Sheath Tumor, Nerve,Sheath Tumors, Nerve,Tumor, Nerve Sheath,Tumors, Nerve Sheath |
|
| D018572 |
Disease-Free Survival |
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. |
Survival, Disease-Free,Disease Free Survival,Survival, Disease Free |
|
-transparent.png){kind=logo}
